SMT201700037B - Nuovi inibitori pirrolici della s-nitrosoglutatione riduttasi come agenti terapeutici - Google Patents

Nuovi inibitori pirrolici della s-nitrosoglutatione riduttasi come agenti terapeutici

Info

Publication number
SMT201700037B
SMT201700037B SM201700037T SM201700037T SMT201700037B SM T201700037 B SMT201700037 B SM T201700037B SM 201700037 T SM201700037 T SM 201700037T SM 201700037 T SM201700037 T SM 201700037T SM T201700037 B SMT201700037 B SM T201700037B
Authority
SM
San Marino
Prior art keywords
nitrosoglutation
pyrrolic
inhibitors
new
reduced
Prior art date
Application number
SM201700037T
Other languages
English (en)
Inventor
Gary J Rosenthal
Jan Wasley
Jian Qiu
Sarah Strong
Xicheng Sun
Original Assignee
N30 Pharmaceuticals Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by N30 Pharmaceuticals Llc filed Critical N30 Pharmaceuticals Llc
Publication of SMT201700037B publication Critical patent/SMT201700037B/it

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/402—1-aryl substituted, e.g. piretanide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/32—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D207/323—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to the ring nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/32—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D207/325—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms with substituted hydrocarbon radicals directly attached to the ring nitrogen atom
    • C07D207/327—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/32—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D207/33—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms with substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D207/337—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
SM201700037T 2008-08-15 2017-01-19 Nuovi inibitori pirrolici della s-nitrosoglutatione riduttasi come agenti terapeutici SMT201700037B (it)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US8931308P 2008-08-15 2008-08-15
US11698208P 2008-11-21 2008-11-21
PCT/US2009/053923 WO2010019903A1 (en) 2008-08-15 2009-08-14 Novel pyrrole inhibitors of s-nitrosoglutathione reductase as therapeutic agents

Publications (1)

Publication Number Publication Date
SMT201700037B true SMT201700037B (it) 2017-03-08

Family

ID=41669340

Family Applications (2)

Application Number Title Priority Date Filing Date
SM201600177T SMT201600177B (it) 2008-08-15 2016-06-16 Nuovi inibitori pirrolici della s-nitrosoglutatione riduttasi come agenti terapeutici
SM201700037T SMT201700037B (it) 2008-08-15 2017-01-19 Nuovi inibitori pirrolici della s-nitrosoglutatione riduttasi come agenti terapeutici

Family Applications Before (1)

Application Number Title Priority Date Filing Date
SM201600177T SMT201600177B (it) 2008-08-15 2016-06-16 Nuovi inibitori pirrolici della s-nitrosoglutatione riduttasi come agenti terapeutici

Country Status (23)

Country Link
US (7) US8691816B2 (it)
EP (3) EP2318006B1 (it)
JP (4) JP2012500219A (it)
KR (1) KR20110042364A (it)
CN (1) CN102186478B (it)
AU (1) AU2009281747B2 (it)
BR (1) BRPI0917017B8 (it)
CA (1) CA2734154C (it)
CY (2) CY1117524T1 (it)
DK (2) DK2315591T3 (it)
ES (2) ES2610158T3 (it)
HK (2) HK1156540A1 (it)
HR (2) HRP20160658T1 (it)
HU (2) HUE027659T2 (it)
IL (1) IL211056A (it)
LT (1) LT2318006T (it)
PL (2) PL2318006T3 (it)
PT (1) PT2318006T (it)
RU (1) RU2500668C2 (it)
SI (2) SI2315591T1 (it)
SM (2) SMT201600177B (it)
WO (2) WO2010019903A1 (it)
ZA (1) ZA201100966B (it)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8455513B2 (en) 2007-01-10 2013-06-04 Aerie Pharmaceuticals, Inc. 6-aminoisoquinoline compounds
US8450344B2 (en) 2008-07-25 2013-05-28 Aerie Pharmaceuticals, Inc. Beta- and gamma-amino-isoquinoline amide compounds and substituted benzamide compounds
AU2009281747B2 (en) * 2008-08-15 2015-01-15 Nivalis Therapeutics, Inc. Novel pyrrole inhibitors of S-nitrosoglutathione reductase as therapeutic agents
JP5524209B2 (ja) * 2008-08-15 2014-06-18 エヌサーティー・ファーマシューティカルズ・インコーポレーテッド Ｓ−ニトロソグルタチオンレダクターゼのピロール阻害剤
DK2318007T3 (da) 2008-08-15 2013-03-25 N30 Pharmaceuticals Inc Nye pyrrol-inhibitorer af s-nitrosoglutathion-reduktase som terapeutiske midler
ES2834451T3 (es) 2009-05-01 2021-06-17 Aerie Pharmaceuticals Inc Inhibidores de mecanismo doble para el tratamiento de enfermedades
WO2011075478A1 (en) * 2009-12-16 2011-06-23 N30 Pharmaceuticals, Llc Novel thiophene inhibitors of s-nitrosoglutathione reductase
EP2592934B1 (en) * 2010-07-16 2015-08-26 Nivalis Therapeutics, Inc. Novel dihydropyridin-2(1h)-one compounds as s-nitrosoglutathione reductase inhibitors and neurokinin-3 receptor antagonists
EP2618666A4 (en) 2010-09-24 2014-04-16 N30 Pharmaceuticals Inc NEW DIHYDROPYRIMIDIN-2 (1H) -ON COMPOUNDS AS NEUROKININ-3 RECEPTOR ANTAGONISTS
PT2624695E (pt) 2010-10-08 2015-12-01 Nivalis Therapeutics Inc Novos compostos de quinolina substituídos como inibidores de s-nitrosoglutationa redutase
CN103328430A (zh) * 2010-12-16 2013-09-25 N30医药品公司 作为s-亚硝基谷胱甘肽还原酶抑制剂的新型取代的双环芳族化合物
US20140135396A1 (en) * 2011-07-05 2014-05-15 Beth Israel Deaconess Medical Center, Inc. Treatment of Acetaminophen-Induced Liver Damage by the Administration of Modulators of Nitric Oxide
US20140113945A1 (en) * 2011-07-05 2014-04-24 N30 Pharmaceuticals, Inc. Novel Pyrrole Inhibitors of S-Nitrosoglutathione Reductase as Therapeutic Agents for Liver Toxicity
US8916555B2 (en) 2012-03-16 2014-12-23 Axikin Pharmaceuticals, Inc. 3,5-diaminopyrazole kinase inhibitors
FI3811943T3 (fi) 2013-03-15 2023-04-14 Aerie Pharmaceuticals Inc Yhdiste käytettäväksi silmäsairauksien hoidossa
NZ631142A (en) 2013-09-18 2016-03-31 Axikin Pharmaceuticals Inc Pharmaceutically acceptable salts of 3,5-diaminopyrazole kinase inhibitors
JP2016535769A (ja) 2013-11-08 2016-11-17 バイエル ファーマ アクチエンゲゼルシャフト キマーゼ阻害薬としての置換されているウラシル類
EP3066098A1 (de) 2013-11-08 2016-09-14 Bayer Pharma Aktiengesellschaft Substituierte uracile und ihre verwendung
JP6364967B2 (ja) * 2014-05-30 2018-08-01 東ソー株式会社 ジチエノベンゾジチオフェンの製造方法
HUE049801T2 (hu) 2014-12-23 2020-10-28 Sma Therapeutics Inc 3,5-diaminopirazol kináz inhibitorok
CN104529995B (zh) * 2014-12-30 2016-04-27 白银摩尔化工有限责任公司 一种空气或纯氧催化氧化溴化氢制备2,3,5-三溴噻吩的方法
CN104557656B (zh) * 2015-01-13 2016-06-01 佛山市赛维斯医药科技有限公司 含卤苯和二烯金刚烷结构的化合物、其制备方法和用途
US10399946B2 (en) 2015-09-10 2019-09-03 Laurel Therapeutics Ltd. Solid forms of an S-Nitrosoglutathione reductase inhibitor
CN105218397B (zh) * 2015-09-25 2017-05-10 济南大学 2‑叠氮甲基‑4‑硝基苯甲酰氯的合成方法
WO2017122754A1 (ja) 2016-01-12 2017-07-20 日本ケミファ株式会社 電位依存性ｔ型カルシウムチャネル阻害剤
US10537557B2 (en) 2016-01-27 2020-01-21 Case Western Reserve University Methods of treating respiratory disorders
EP3795563A1 (en) 2016-03-31 2021-03-24 Oncternal Therapeutics, Inc. Indoline analogs and uses thereof
TW201806596A (zh) * 2016-08-01 2018-03-01 中央研究院 抗病毒劑
US11389441B2 (en) 2016-08-31 2022-07-19 Aerie Pharmaceuticals, Inc. Ophthalmic compositions
US9840468B1 (en) 2016-12-30 2017-12-12 Aerie Pharmaceuticals, Inc. Methods for the preparation of 6-aminoisoquinoline
JP2020515583A (ja) 2017-03-31 2020-05-28 アエリエ ファーマシューティカルズ インコーポレイテッド アリールシクロプロピル−アミノ−イソキノリニルアミド化合物
JP2020100564A (ja) * 2017-04-03 2020-07-02 京都薬品工業株式会社 リードスルー誘導剤およびその医薬用途
US11655244B2 (en) * 2017-04-11 2023-05-23 Gsno Therapeutics, Inc. Carbazole compounds and methods of use thereof
EP3634460A4 (en) 2017-05-08 2021-03-03 Musc Foundation for Research Development S-NITROSOGLUTATHION (GSNO) AND GSNO-REDUCTASE INHIBITORS FOR USE IN THERAPY
WO2020056345A1 (en) 2018-09-14 2020-03-19 Aerie Pharmaceuticals, Inc. Aryl cyclopropyl-amino-isoquinolinyl amide compounds
CN110015963A (zh) * 2019-04-12 2019-07-16 上海优合生物科技有限公司 一种2-氯-6-甲基苯胺的制备方法
US20230357154A1 (en) * 2019-08-08 2023-11-09 Treventis Corporation Butyrylcholinesterase compounds and use in diseases of the nervous system
CN112574193B (zh) * 2020-12-31 2022-05-17 南京医科大学 一类口服gsnor抑制剂及其药物用途

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3168529A (en) 1962-06-14 1965-02-02 Parke Davis & Co 1-(p-lower alkanoylphenyl)-5-arylpyrrole-2-propionic acid compounds
US3168527A (en) 1962-06-14 1965-02-02 Parke Davis & Co 1-aryl-5-(p-fluorophenyl)-pyrrole-2-propionic acid compounds
US3168528A (en) * 1962-06-14 1965-02-02 Parke Davis & Co 1-(p-nitrophenyl) and 1-(p-cyanophenyl)-5-arylpyrrole-2-propionic acid compounds
GB997043A (en) 1962-06-14 1965-06-30 Parke Davis & Co Derivatives of 1,5-diarylpyrrole-2-propionic acid
US3168531A (en) 1963-06-12 1965-02-02 Parke Davis & Co 1-aryl-5-(p-lower alkoxyphenyl)-pyrrole-2-propionic acid compounds
US3168532A (en) 1963-06-12 1965-02-02 Parke Davis & Co 1, 5-diarylpyrrole-2-propionic acid compounds
FR1393615A (fr) 1964-03-05 1965-03-26 Inst Organiycheskoi Khim Im N Procédé de préparation de la nu-vinylpyrrolidone
US3427305A (en) * 1966-11-01 1969-02-11 Searle & Co 5 - ((halo/alkoxy)phenyl) - 1 - (p - sulfonamido(phenyl/benzyl)) - 2 - pyrrolepropionic acids
US3752826A (en) 1970-01-26 1973-08-14 Mcneilab Inc Aroyl substituted pyrroles
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4694018A (en) * 1985-11-29 1987-09-15 G. D. Serale & Co. Substituted 1,5-diphenyl-2-pyrrolepropionic acids and derivatives
US4792568A (en) 1986-04-14 1988-12-20 Rorer Pharmaceutical Corporation Aryl pyrroles as useful antiallergy compounds
US4826869A (en) * 1988-02-19 1989-05-02 Syntex (U.S.A.) Inc. N-(lower alkyl)-2-(3'ureidobenzyl)pyrrolidines
US5189051A (en) * 1990-05-10 1993-02-23 E. I. Du Pont De Nemours And Company Treatment of glaucoma and ocular hypertension with pyrrole angiotensin-II receptor antagonists
DE4036706A1 (de) 1990-11-17 1992-05-21 Hoechst Ag Verfahren zur behandlung der cardialen sowie der vasculaeren hypertrophie und hyperplasie
US6008368A (en) 1993-04-28 1999-12-28 G. D. Searle & Co. Pharmaceutical compositions for treatment of circulatory disorders using N-substituted (α-imidazolyl-toluyl) pyrrole aniotensin II antagonists
US5187271A (en) * 1991-02-28 1993-02-16 G. D. Searle & Co. N-substituted (α-imidazolyl-toluyl) pyrrole compounds for treatment of circulatory disorders
US5451597A (en) 1993-05-27 1995-09-19 G.D. Searle & Co. Treatment of circulatory disorders using n-substituted (α-imidazolyl-toluyl) pyrrole angiotensin II antagonists
US5789440A (en) 1993-11-19 1998-08-04 Warner-Lambert Company 5,6-dihydropyrone derivatives as protease inhibitors and antiviral agents
US6057367A (en) 1996-08-30 2000-05-02 Duke University Manipulating nitrosative stress to kill pathologic microbes, pathologic helminths and pathologically proliferating cells or to upregulate nitrosative stress defenses
EP0952828B1 (en) * 1996-11-13 2006-08-16 Cold Spring Harbor Laboratory Therapeutic uses for nitric oxide inhibitors
DK0946507T3 (da) * 1996-12-10 2004-01-26 Searle & Co Substituerede pyrrolylforbindelser til behandling af inflammation
FR2782720B1 (fr) * 1998-09-01 2001-10-12 Oreal Utilisation en teinture capillaire de condensats de quinoline-5,8-diones ou de quinoxaline-5,8-diones et de pyrroles, anilines ou indoles substitues
US6355812B1 (en) 1999-06-11 2002-03-12 Orth-Mcneil Pharmaceutical, Inc. Methods for the synthesis of dioxoalkanoic acid compounds
US6589978B2 (en) * 2000-06-30 2003-07-08 Hoffman-La Roche Inc. 1-sulfonyl pyrrolidine derivatives
US6359182B1 (en) 2000-10-26 2002-03-19 Duke University C-nitroso compounds and use thereof
US7049308B2 (en) * 2000-10-26 2006-05-23 Duke University C-nitroso compounds and use thereof
US7179791B2 (en) * 2001-01-11 2007-02-20 Duke University Inhibiting GS-FDH to modulate NO bioactivity
WO2003000249A1 (fr) * 2001-06-26 2003-01-03 Takeda Chemical Industries, Ltd. Regulateur de la fonction du recepteur relatif aux retinoides
GB0119172D0 (en) * 2001-08-06 2001-09-26 Melacure Therapeutics Ab Phenyl pyrrole derivatives
GB0212785D0 (en) * 2002-05-31 2002-07-10 Glaxo Group Ltd Compounds
AU2003259749A1 (en) * 2002-08-12 2004-02-25 Sugen, Inc. 3-pyrrolyl-pyridopyrazoles and 3-pyrrolyl-indazoles as novel kinase inhibitors
GB0229581D0 (en) 2002-12-19 2003-01-22 Cyclacel Ltd Use
US20060270628A1 (en) 2003-04-29 2006-11-30 Jagattaran Das Antiinfective 1,2,3-triazole derivatives, process for their preparation and pharmaceutical compositions containing them
US20050014697A1 (en) 2003-06-04 2005-01-20 Stamler Jonathan S. Compositions and methods for modulating S-nitrosoglutathione reductase
US7754751B2 (en) 2004-03-15 2010-07-13 Yung Shin Pharmaceutical Ind. Co., Ltd. Preferential inhibition of release of pro-inflammatory cytokines
MY144903A (en) 2004-06-17 2011-11-30 Novartis Ag Pyrrolopyridine derivatives and their use as crth2 antagonists
CA2573426C (en) * 2004-07-30 2015-11-17 Exelixis, Inc. Pyrrole derivatives as pharmaceutical agents
CN101006052B (zh) * 2004-07-30 2013-11-06 埃克塞利希斯股份有限公司 作为药用制剂的吡咯衍生物
FR2881426B1 (fr) * 2005-02-03 2007-03-30 Aventis Pharma Sa Pyrolles et imidazoles substitues, compositions les contenant, procede de frabrication et utilisation
JP2006290791A (ja) 2005-04-11 2006-10-26 Astellas Pharma Inc アゾール置換スルホニルベンゼン誘導体
WO2006133926A1 (en) 2005-06-17 2006-12-21 Carex Sa Pyrazole derivates as cannabinoid receptor modulators
EP1910337A2 (en) * 2005-06-24 2008-04-16 Genelabs Technologies, Inc. Heteroaryl derivatives for treating viruses
WO2007009083A2 (en) 2005-07-12 2007-01-18 Acadia Pharmaceuticals Inc. Compounds with activity at retinoic acid receptors
WO2009076665A1 (en) 2007-12-13 2009-06-18 Indiana University Research And Technology Corporation Materials and methods for inhibiting mammalian s-nitrosoglutathione reductase
US20110104308A1 (en) 2008-05-09 2011-05-05 Duke University Treatment For Diseases Relying On Discovery That Thioredoxin Mediates Nitric Oxide
AU2009281747B2 (en) 2008-08-15 2015-01-15 Nivalis Therapeutics, Inc. Novel pyrrole inhibitors of S-nitrosoglutathione reductase as therapeutic agents
JP5524209B2 (ja) * 2008-08-15 2014-06-18 エヌサーティー・ファーマシューティカルズ・インコーポレーテッド Ｓ−ニトロソグルタチオンレダクターゼのピロール阻害剤
DK2318007T3 (da) 2008-08-15 2013-03-25 N30 Pharmaceuticals Inc Nye pyrrol-inhibitorer af s-nitrosoglutathion-reduktase som terapeutiske midler
WO2010107476A1 (en) * 2009-03-19 2010-09-23 Duke University Inhibiting gsnor
WO2011075478A1 (en) 2009-12-16 2011-06-23 N30 Pharmaceuticals, Llc Novel thiophene inhibitors of s-nitrosoglutathione reductase
US20140113945A1 (en) 2011-07-05 2014-04-24 N30 Pharmaceuticals, Inc. Novel Pyrrole Inhibitors of S-Nitrosoglutathione Reductase as Therapeutic Agents for Liver Toxicity

Also Published As

Publication number Publication date
EP2315591B1 (en) 2016-03-16
US9814700B2 (en) 2017-11-14
DK2315591T3 (en) 2016-06-06
US20140194425A1 (en) 2014-07-10
RU2500668C2 (ru) 2013-12-10
ZA201100966B (en) 2012-04-25
DK2318006T3 (en) 2017-01-23
SMT201600177B (it) 2016-08-31
AU2009281747B2 (en) 2015-01-15
BRPI0917017B1 (pt) 2019-10-29
IL211056A0 (en) 2011-04-28
HK1156846A1 (zh) 2012-06-22
CY1117524T1 (el) 2017-04-26
US20170049750A1 (en) 2017-02-23
CN102186478A (zh) 2011-09-14
JP2015038133A (ja) 2015-02-26
CY1118454T1 (el) 2017-07-12
SI2315591T1 (sl) 2016-06-30
PT2318006T (pt) 2017-01-13
JP2015038132A (ja) 2015-02-26
US8691816B2 (en) 2014-04-08
HRP20160658T1 (hr) 2016-07-15
AU2009281747A1 (en) 2010-02-18
ES2610158T3 (es) 2017-04-26
US20140155447A1 (en) 2014-06-05
EP3069721A1 (en) 2016-09-21
JP5917650B2 (ja) 2016-05-18
PL2318006T3 (pl) 2017-06-30
US8957105B2 (en) 2015-02-17
HK1156540A1 (zh) 2012-06-15
BRPI0917017B8 (pt) 2021-05-25
US20160045477A1 (en) 2016-02-18
WO2010019910A1 (en) 2010-02-18
EP2318006A1 (en) 2011-05-11
US20150126570A1 (en) 2015-05-07
WO2010019903A1 (en) 2010-02-18
CN102186478B (zh) 2013-10-02
EP2315591A4 (en) 2013-01-02
JP2012500219A (ja) 2012-01-05
PL2315591T3 (pl) 2016-09-30
ES2572615T3 (es) 2016-06-01
US9138427B2 (en) 2015-09-22
US20110144110A1 (en) 2011-06-16
HUE031580T2 (en) 2017-07-28
KR20110042364A (ko) 2011-04-26
HUE027659T2 (en) 2016-11-28
EP2318006A4 (en) 2011-12-28
CA2734154C (en) 2017-07-11
HRP20170019T1 (hr) 2017-03-10
RU2011109339A (ru) 2012-09-20
US9498466B2 (en) 2016-11-22
US9180119B2 (en) 2015-11-10
SI2318006T1 (sl) 2017-01-31
LT2318006T (lt) 2017-01-10
BRPI0917017A2 (pt) 2016-02-16
US8673961B2 (en) 2014-03-18
US20110144180A1 (en) 2011-06-16
EP2318006B1 (en) 2016-10-12
CA2734154A1 (en) 2010-02-18
IL211056A (en) 2014-04-30
EP2315591A1 (en) 2011-05-04
JP2012500216A (ja) 2012-01-05

Similar Documents

Publication Publication Date Title
SMT201700037B (it) Nuovi inibitori pirrolici della s-nitrosoglutatione riduttasi come agenti terapeutici
SMT201600278B (it) Inibitori della benzossazolo chinasi e metodi d'uso
SMT201500262B (it) Trattamento della sclerosi multipla con laquinimod
DK3130923T3 (da) Terapeutiske fremgangsmåder i forbindelse med cancerstamceller
BR112012001325A2 (pt) tratamento de distúrbios do fígado com inibidaores de pi3k
DK2276767T3 (da) Benzopyran- og benzoxepinforbindelser som pi3k-inhibitorer og anvendelsesfremgangsmåder
EP2026843A4 (en) THERAPEUTIC USES OF RTP801L INHIBITORS
DK2389352T3 (da) Arginaseinhibitorer og anvendelsesfremgangsmåder
DK2308885T3 (da) Nye forbindelser og fremgangsmåder for terapi
BRPI0922823A2 (pt) Combinações e modos de administração de agentes terapêuticos e terapia de combinação
BRPI0916931A2 (pt) agentes terapêuticos
ATE543816T1 (de) Azacycloalkanderivate als inhibitoren von stearoyl-coenzym-a-delta-9-desaturase
HK1156620A1 (en) Novel pyrrole inhibitors of s-nitrosoglutathione reductase as therapeutic agents
BRPI0922344A2 (pt) inibidores de tfpi e métodos de uso
SMT201500071B (it) Agenti antimalarici che sono inibitori della diidro-orotato deidrogenasi
SMT201600073B (it) Inibitori della mitosi per aumentare l'apoptosi in terapia
IL206891A0 (en) Therapeutic inhibitors of pai-1 function and methods of their use
SMT201600156B (it) Trattamento dell’osteoartrite
ITFI20070288A1 (it) Inibitori delle deacetilasi istoniche
BRPI0714318A2 (pt) Utilização de 2-benzoil-imidazopiridinas em terapêutica
FI8286U1 (fi) Kunto- ja terapiaväline
TH0801005083A (th) สารประกอบ องค์ประกอบ และกรรมวิธีการใช้ตัวยับยั้ง parp
TH0801000575A (th) บรรดาตัวยับยั้งของการออกฤทธิ์ Akt
TH0801006114A (th) สารประกอบและองค์ประกอบใหม่ และวิธีการของการใช้
TH0801000600A (th) การร่วมกันของสารบำบัดรักษาสำหรับการบำบัดโรคมะเร็ง